Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for share ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

The latest update is out from Inmune Bio ( (INMB) ).

In a recent transaction, Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc. (NASDAQ: INMB), a company specializing in biological products, has increased his stake in the company by ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral ...

Company News Published09/03/2024, 10:48 AM INmune Bio stock hits 52-week low at $6.4 amid market challenges View all comments (0)0 INMB -3.59% ...

In a challenging year for biotechnology firms, INmune Bio Inc. (NASDAQ: INMB) stock has touched a 52-week low, dipping to $4.8. The company, known for its innovative approaches to treating ...

INMUNE BIO Hedge Fund Activity We have seen 46 institutional investors add shares of INMUNE BIO stock to their portfolio, and 19 decrease their positions in their most recent quarter.

Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator. Date: March 2, 2023 Time: 4:30 PM Eastern Time Participant Dial-in: 1-877-407-0784 ...